Skip to content
2000
Volume 32, Issue 13
  • ISSN: 0929-8673
  • E-ISSN: 1875-533X

Abstract

Background

Early diagnosis of renal dysfunction in β-thalassemia major (β-TM) may help take specific measures to delay irreversible damage and renal failure. Therefore, the present meta-analysis aimed to compare biochemical markers of premature renal dysfunction between β-TM and healthy subjects and identify renal issues' prevalence in patients with β-TM.

Methods

We searched PubMed, Cumulative Index of Nursing and Allied Health Literature (CINAHL), Medline, Scopus, Web of Science, ScienceDirect, ProQuest, Google Scholar, and State Inpatient Databases (SIDs) without any language constraints for all relevant articles published up to April 2019.

Results

Out of 1458 articles published up to April 2019, 24 case-control and 22 cross-sectional studies were investigated. The investigated levels of serum phosphorus, uric acid (UA), cystatin C, and ferritin were significantly different between β-TM patients and controls. The albumin/creatinine ratio (ACR), N-acetyl-β-D-glucosaminidase/creatinine (NAG/Cr) ratio, urinary and serum β2 microglobulin (β2MG), and serum ferritin levels were significantly higher in β-TM patients than in healthy individuals. However, glomerular filtration rate, creatinine clearance, and pretransfusion hemoglobin indicated a significantly lower rate. The general prevalence of renal glomerular and/or tubular defects in patients with β-TM was 50.22%.

Conclusion

Urinary NAG, β2MG, ACR, and S may be early markers of renal dysfunction in patients with β-thalassemia major. An observation of elevated levels of these markers despite normal levels of other markers of renal dysfunction may indicate primary, subclinical injury to the renal tubules and glomeruli.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cmc/10.2174/0109298673250805230922054406
2023-10-26
2025-10-04

  • From This Site

    /content/journals/cmc/10.2174/0109298673250805230922054406
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Abdul-ZahraH.A.I. HassanM.K. AhmedB.A.A.H. Health-related quality of life in children and adolescents with β-thalassemia major on different iron chelators in basra, iraq.J. Pediatr. Hematol. Oncol.201638750351110.1097/MPH.000000000000066327606437
     [Google Scholar]
  2. CaocciG. La NasaG. d’AlojaE. VaccaA. PirasE. PintorM. DemontisR. PisuS. Ethical issues of unrelated hematopoietic stem cell transplantation in adult thalassemia patients.BMC Med. Ethics2011121410.1186/1472‑6939‑12‑421385429
     [Google Scholar]
  3. DebaunM.R. Frei-JonesM. VichinskyE. Thalassemia syndromes. nelson textbook of pediatrics.19th PhiladelphiaElsevier Sanders201116741677
     [Google Scholar]
  4. WuH.P. LinC.L. ChangY.C. WuK.H. LeiR.L. PengC.T. WengT. TaiY.M. ChaoY.H. Survival and complication rates in patients with thalassemia major in Taiwan.Pediatr. Blood Cancer201764113513810.1002/pbc.2618127571924
     [Google Scholar]
  5. Borgna-PignattiC. CappelliniM.D. De StefanoP. Del VecchioG.C. ForniG.L. GamberiniM.R. GhilardiR. PigaA. RomeoM.A. ZhaoH. CnaanA. Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major.Blood200610793733373710.1182/blood‑2005‑07‑293316373663
     [Google Scholar]
  6. ArianM. MemarianR. OghazianM.B. VakilianF. BadieeZ. The effect of a holistic care program on the reduction of iron overload in patients with beta-thalassemia major: A randomized clinical trial.Iran. Red. Crescent Med. J.2018204e6082010.5812/ircmj.60820
     [Google Scholar]
  7. MusallamK.M. TaherA.T. Mechanisms of renal disease in β-thalassemia.J. Am. Soc. Nephrol.20122381299130210.1681/ASN.201111107022677552
     [Google Scholar]
  8. EconomouM. PrintzaN. TeliA. TzimouliV. TsatraI. PapachristouF. Athanassiou-MetaxaM. Renal dysfunction in patients with beta-thalassemia major receiving iron chelation therapy either with deferoxamine and deferiprone or with deferasirox.Acta Haematol.2010123314815210.1159/00028723820185899
     [Google Scholar]
  9. HeymanS.N. KhamaisiM. RosenS. RosenbergerC. Renal parenchymal hypoxia, hypoxia response and the progression of chronic kidney disease.Am. J. Nephrol.2008286998100610.1159/00014607518635927
     [Google Scholar]
  10. NangakuM. Chronic hypoxia and tubulointerstitial injury: A final common pathway to end-stage renal failure.J. Am. Soc. Nephrol.2006171172510.1681/ASN.200507075716291837
     [Google Scholar]
  11. RicchiP. AmmirabileM. CostantiniS. Di MatolaT. SpasianoA. GennaM.L. CinqueP. ProssomaritiL. Splenectomy is a risk factor for developing hyperuricemia and nephrolithiasis in patients with thalassemia intermedia: A retrospective study.Blood Cells Mol. Dis.2012493-413313510.1016/j.bcmd.2012.05.01222705193
     [Google Scholar]
  12. LaiM.E. SpigaA. VacquerS. CartaM.P. CorriasC. PonticelliC. Renal function in patients with -thalassaemia major: a long-term follow-up study.Nephrol. Dial. Transplant.20122793547355110.1093/ndt/gfs16922695832
     [Google Scholar]
  13. MazaheriM. Impaired renal tubular function in pediatric patients with β-thalassemia major.Koomesh200910211924
     [Google Scholar]
  14. PonticelliC. MusallamK.M. CianciulliP. CappelliniM.D. Renal complications in transfusion-dependent beta thalassaemia.Blood Rev.201024623924410.1016/j.blre.2010.08.00420850917
     [Google Scholar]
  15. TanakaA. SuemaruK. ArakiH. A new approach for evaluating renal function and its practical application.J. Pharmacol. Sci.200710511510.1254/jphs.CP007005817827872
     [Google Scholar]
  16. Sadeghi-BojdS. HashemiM. KarimiM. Renal tubular function in patients with β-thalassaemia major in Zahedan, southeast Iran.Singapore Med. J.200849541041218465053
     [Google Scholar]
  17. SmolkinV. HalevyR. LevinC. MinesM. SakranW. IliaK. KorenA. Renal function in children with β-thalassemia major and thalassemia intermedia.Pediatr. Nephrol.200823101847185110.1007/s00467‑008‑0897‑818581145
     [Google Scholar]
  18. AldudakB. BayazitA.K. NoyanA. ÖzelA. AnaratA. SasmazI. KilinçY. GaliE. AnaratR. DikmenN. Renal function in pediatric patients with β-thalassemia major.Pediatr. Nephrol.2000151-210911210.1007/s00467000043411095025
     [Google Scholar]
  19. DoddamaniP. SumaM.N. RaviM.D. PrashantA. VishwanathP. NagalakshmiC.S. Importance of assessment of microalbuminuria in β-thalassemia major patients.Int. J. Health Allied Sci.20121423510.4103/2278‑344X.107864
     [Google Scholar]
  20. MaleknejadS. HeidarzadehA. GhandiY. Urine β2 Microglobulin and other biochemical indices in β thalassemia Major.Acta Med. Iran.2009476443446
     [Google Scholar]
  21. MoolaS. MunnZ. TufanaruC. AromatarisE. SearsK. SfetcuR. Systematic reviews of etiology and risk.Joanna Briggs Institute Reviewer's Manual The Joanna Briggs Institute2017Available from: https://reviewersmanual.joannabriggs.org/
    [Google Scholar]
  22. HigginsJ.P.T. ThompsonS.G. DeeksJ.J. AltmanD.G. Measuring inconsistency in meta-analyses.BMJ2003327741455756010.1136/bmj.327.7414.55712958120
     [Google Scholar]
  23. ZafariM. AghamohammadyA. MosavyM. Renal function in thalassemia major patients who treated by Desferal.Banglad. J. Med. Sci.2018171586110.3329/bjms.v17i1.35281
     [Google Scholar]
  24. SabzghabaeiF. DarnahalM. AzarkeivanA. Renal function in β-thalassemia major receiving desferal versus deferasirox.J. Renal Inj. Prev.20177314815110.15171/jrip.2018.37
     [Google Scholar]
  25. El AlfyM. SariT.T. LeeC.L. TrictaF. El-BeshlawyA. The safety, tolerability, and efficacy of a liquid formulation of deferiprone in young children with transfusional iron overload.J. Pediatr. Hematol. Oncol.201032860160510.1097/MPH.0b013e3181ec0f1320921906
     [Google Scholar]
  26. AnnayevA. KarakaşZ. KaramanS. YalçınerA. YilmazA. EmreS. Glomerular and tubular functions in children and adults with transfusion-dependent thalassemia.Turk. J. Haematol.2018351667010.4274/tjh.2017.026628753129
     [Google Scholar]
  27. ShoeibSA El HafezMAA El HamidAEA KhodairSA AmerHG ElmohsenEAA Glomerular dysfunction in adult patients with β-thalassemia major.Open Acce. Blood. Res. Transfus. J.2017135662
     [Google Scholar]
  28. NickavarA. QmarsiA. AnsariS. ZareiE. Kidney function in patients with different variants of beta-thalassemia.Iran. J. Kidney Dis.201711213213728270645
     [Google Scholar]
  29. HashemiehM. RadfarM. AzarkeivanA. Hosseini TabatabaeiS.M.T. NikbakhtS. YaseriM. SheibaniK. Renal hemosiderosis among iranian transfusion dependent β-thalassemia major patients.Int. J. Hematol. Oncol. Stem Cell Res.201711213313828875008
     [Google Scholar]
  30. BekhitO.E.L. El DashH.H. AhmedM.S. Early detection of kidney dysfunction in egyptian patients with beta-thalassemia major.Gaz. Egypt. Paediatr. Assoc.2017653858910.1016/j.epag.2017.02.002
     [Google Scholar]
  31. BehairyO.G. Abd AlmonaemE. AbedN. Abdel HaieaO. ZakariaR. AbdEllatyR. AsrE.H. MansourA. AbdelrahmanA. ElhadyH. Role of serum cystatin-C and beta-2 microglobulin as early markers of renal dysfunction in children with beta thalassemia major.Int. J. Nephrol. Renovasc. Dis.20171026126810.2147/IJNRD.S14282428979155
     [Google Scholar]
  32. FallahzadehM.H. FallahzadehM.K. ShahriariM. RastegarS. DerakhshanA. FallahzadehM.A. Hematuria in patients with beta-thalassemia major.Iran. J. Kidney Dis.20104213313620404424
     [Google Scholar]
  33. ElbedewyT GawalyA Abd El-NabyA. Serum cystatin-c and urinary n-acetyl-beta-d-glucosaminidase as biomarkers for early renal dysfunction in adult egyptian patients with beta-thalassemia major.Leuk. Res.201649S22
     [Google Scholar]
  34. DeveciB. KurtogluA. KurtogluE. SalimO. ToptasT. Documentation of renal glomerular and tubular impairment and glomerular hyperfiltration in multitransfused patients with beta thalassemia.Ann. Hematol.201695337538110.1007/s00277‑015‑2561‑226596972
     [Google Scholar]
  35. UzunE. BalcıY.I. YükselS. AralY.Z. AybekH. AkdağB. Glomerular and tubular functions in children with different forms of beta thalassemia.Ren. Fail.20153791414141810.3109/0886022X.2015.107731426365703
     [Google Scholar]
  36. ŞenV. EceA. UlucaÜ. SökerM. GüneşA. Kaplanİ. Tanİ. YelS. MeteN. SahinC. Urinary early kidney injury molecules in children with beta-thalassemia major.Ren. Fail.201537460761310.3109/0886022X.2015.100787125656833
     [Google Scholar]
  37. PigaA. FracchiaS. LaiM.E. CappelliniM.D. HirschbergR. HabrD. WegenerA. BouillaudE. ForniG.L. Deferasirox effect on renal haemodynamic parameters in patients with transfusion‐dependent β thalassaemia.Br. J. Haematol.2015168688289010.1111/bjh.1321725402221
     [Google Scholar]
  38. MiloG. Feige Gross NevoR. PazgalI. Gafter-GviliA. ShpilbergO. GafterU. ErmanA. StarkP. GFR in patients with β-thalassemia major.Clin. J. Am. Soc. Nephrol.20151081350135610.2215/CJN.1218121425964308
     [Google Scholar]
  39. KacarA.G. SilfelerI. KacarA. PekunF. TurkkanE. AdalE. Levels of beta-2 microglobulin and cystatin C in beta thalassemia major patients.J. Clin. Analy. Med.201563269273
     [Google Scholar]
  40. TantawyA.A. El BablawyN. AdlyA.A. EbeidF.S. Early predictors of renal dysfunction in Egyptian patients with β-thalassemia major and intermedia.Mediterr. J. Hematol. Infect. Dis.201461e201405710.4084/mjhid.2014.05725237470
     [Google Scholar]
  41. GokceM. KupH. TugcuD. SalciogluZ. AydoganG. Insidious renal damage in patients with thalassemia major: Is it more serious than appreciated?J. Hematol. Thromb.20142173
     [Google Scholar]
  42. DeeC.M.A. CheukD.K.L. HaS.Y. ChiangA.K.S. ChanG.C.F. Incidence of deferasirox-associated renal tubular dysfunction in children and young adults with beta-thalassaemia.Br. J. Haematol.2014167343443610.1111/bjh.1300224989901
     [Google Scholar]
  43. AdlyA.A.M. ToaimaD.N. MohamedN.R. Abu El SeoudK.M. Subclinical renal abnormalities in young thalassemia major and intermedia patients and its relation to chelation therapy.Egypt. J. Med. Hum. Genet.201415436937710.1016/j.ejmhg.2014.06.004
     [Google Scholar]
  44. AliB.A. MahmoudA.M. Frequency of glomerular dysfunction in children with beta thalassaemia major.Sultan Qaboos Univ. Med. J.2014141889410.12816/000334124516760
     [Google Scholar]
  45. Al-KhaboriM. BhandariS. Al-RasadiK. MevadaS. Al-DhuhliH. Al-KemyaniN. DaarS. Correlation of iron overload and glomerular filtration rate estimated by cystatin C in patients with β-thalassemia major.Hemoglobin201438536536810.3109/03630269.2014.94431425074643
     [Google Scholar]
  46. HuangW.F. ChouH.C. TsaiY.W. HsiaoF.Y. Safety of deferasirox: A retrospective cohort study on the risks of gastrointestinal, liver and renal events.Pharmacoepidemiol. Drug Saf.201423111176118210.1002/pds.365724946110
     [Google Scholar]
  47. EfthimiaV. NeokleousN. AgapidouA. EconomouM. VetsiouE. TeliA. PerifanisV. Nephrolithiasis in beta thalassemia major patients treated with deferasirox: An advent or an adverse event? A single Greek center experience.Ann. Hematol.201392226326510.1007/s00277‑012‑1558‑322933235
     [Google Scholar]
  48. Mahmoodi NesheliH. SorkhiH. TamaddoniA. KarimiM. PournasrollahM. HajiahmadiM. Correlation of renal function with liver iron overload in beta-thalassemia major patients.J. Babol. Univ. Med. Sci.20131511824
     [Google Scholar]
  49. AydinokY. UnalS. OymakY. VerginC. TürkerZ.D. YildizD. YesilipekA. Observational study comparing long-term safety and efficacy of Deferasirox with Desferrioxamine therapy in chelation-naïve children with transfusional iron overload.Eur. J. Haematol.201288543143810.1111/j.1600‑0609.2012.01769.x22335829
     [Google Scholar]
  50. DubourgL. LaurainC. RanchinB. PondarréC. Hadj-AïssaA. Sigaudo-RousselD. CochatP. Deferasirox-induced renal impairment in children: An increasing concern for pediatricians.Pediatr. Nephrol.201227112115212210.1007/s00467‑012‑2170‑422527533
     [Google Scholar]
  51. Mula-AbedW-A.S. Al-HashmiH.S. Al-MuslahiM.N. Indicators of renal glomerular and tubular functions in patients with beta-thalassaemia major: A cross sectional study at the Royal Hospital, Oman.Sultan Qaboos Univ. Med. J.2011111697621509211
     [Google Scholar]
  52. MalakiM SorkhabiRS ShoaranM ShafigheB Beta thalassemia major: The effect of age on glomerular filtration rate.Saudi. J. Kidney. Dis. Transpl.2011225963968
     [Google Scholar]
  53. JafariH.M. VahidshahiK. KosaryanM. KaramiH. Reza MahdaviM. EhteshamiS. Major beta-thalassemia, use of desferiexamine and renal proximal tubular damage.Bratisl. Lek Listy2011112527828121682083
     [Google Scholar]
  54. AhmadzadehA JalaliA AssarS KhalilianH ZandianK PedramM Renal tubular dysfunction in pediatric patients with beta-thalassemia major.Saudi. J. Kidney. Dis. Transpl.2011223497500
     [Google Scholar]
  55. JalaliA. KhalilianH. AhmadzadehA. SarvestaniS. RahimF. ZandianK. AsarS. Renal function in transfusion-dependent pediatric beta-thalassemia major patients.Hematology201116424925410.1179/102453311X1295301576766221756543
     [Google Scholar]
  56. HamedE.A. ElMelegyN.T. Renal Functions in pediatric patients with beta-thalassemia major: Relation to chelation therapy: original prospective study.Ital. J. Pediatr.20103613910.1186/1824‑7288‑36‑3920500848
     [Google Scholar]
  57. Salman OghliT. GFR in Patients with β-Thalassemia MajorMD thesisTabriz: Tabriz University of Medical Science2010
     [Google Scholar]
  58. PapassotiriouI. MargeliA. HantziE. DelaportaP. SergouniotiA. GoussetisE. LadisV. KattamisA. Cystatin C levels in patients with β-thalassemia during deferasirox treatment.Blood Cells Mol. Dis.201044315215510.1016/j.bcmd.2010.01.00120110177
     [Google Scholar]
  59. MohkamM. ShamsianB.S. GharibA. NarimanS. ArzanianM.T. Early markers of renal dysfunction in patients with beta-thalassemia major.Pediatr. Nephrol.200823697197610.1007/s00467‑008‑0753‑x18288499
     [Google Scholar]
  60. AliD MehranK MoghaddamAG Comparative evaluation of renal findings in beta-thalassemia major and intermedia.Saudi. J. Kidney. Dis. Transpl.2008192206209
     [Google Scholar]
  61. KoliakosG. PapachristouF. KoussiA. PerifanisV. TsatraI. SouliouE. AthanasiouM. Urine biochemical markers of early renal dysfunction are associated with iron overload in β-thalassaemia.Clin. Lab. Haematol.200325210510910.1046/j.1365‑2257.2003.00507.x12641614
     [Google Scholar]
  62. Kassab-ChekirA. LaradiS. FerchichiS. Haj KhelilA. FekiM. AmriF. SelmiH. BejaouiM. MiledA. Oxidant, antioxidant status and metabolic data in patients with beta-thalassemia.Clin. Chim. Acta20033381-2798610.1016/j.cccn.2003.07.01014637270
     [Google Scholar]
  63. Hosseini TabatabaeiS.M. Tabatabai VakiliS.M. GFR in patients with b-thalassemia major.Zahedan J. Res. Med. Sci.200022915
     [Google Scholar]
  64. BuhlL. MuirheadD.E. PrentisP.F. Renal hemosiderosis due to thalassemia: A light and electron microscopy study with electron probe X-ray microanalysis.Ultrastruct. Pathol.199317216918310.3109/019131293090840378316965
     [Google Scholar]
  65. NegahiA. AshrafiM. Calcium and phosphorus serum levels in thalassemic patients with convulsion history, Bandar Abbas, Iran.Hormozgan Med. J.2006101714
     [Google Scholar]
  66. ArianM. SoleimaniM. Fakhr-MovahediA. OghazianM.B. BadieeZ. Quality of life in patients with thalassemia major: A concept analysis using Rodgers’ evolutionary method.Int. J. Pediatr.2020851119711217
     [Google Scholar]
  67. ArianM. VaismoradiM. BadieeZ. SoleimaniM. Understanding the impact of COVID-19 pandemic on health-related quality of life amongst Iranian patients with beta thalassemia major: A grounded theory.Prim. Health Care Res. Dev.202122e6710.1017/S146342362100013X34753533
     [Google Scholar]
  68. KorenG. Kochavi-AtiyaY. BenturY. OlivieriN.F. The effects of subcutaneous deferoxamine administration on renal function in thalassemia major.Int. J. Hematol.19915453713751756248
     [Google Scholar]
  69. FujitaH. NaritaT. MoriiT. ShimotomaiiT. YoshiokaN. KakeiM. ItoS. Increased urinary excretion of N-acetylglucosaminidase in subjects with impaired glucose tolerance.Ren. Fail.2002241697510.1081/JDI‑12000266211921700
     [Google Scholar]
  70. NickolasT.L. BaraschJ. DevarajanP. Biomarkers in acute and chronic kidney disease.Curr. Opin. Nephrol. Hypertens.200817212713210.1097/MNH.0b013e3282f4e52518277143
     [Google Scholar]
  71. LinkG. AthiasP. GrynbergA. PinsonA. HershkoC. Effect of iron loading on transmembrane potential, contraction, and automaticity of rat ventricular muscle cells in culture.J. Lab. Clin. Med.198911311031112909644
     [Google Scholar]
  72. ThomasC.E. MorehouseL.A. AustS.D. Ferritin and superoxide-dependent lipid peroxidation.J. Biol. Chem.198526063275328010.1016/S0021‑9258(19)83617‑72982854
     [Google Scholar]
  73. ColeN.I. SucklingR.J. DesilvaV. HeF.J. MacGregorG.A. SwiftP.A. Serum sodium concentration and the progression of established chronic kidney disease.J. Nephrol.201932225926410.1007/s40620‑018‑0541‑z30328093
     [Google Scholar]
  74. NakajimaK. OdaE. KandaE. The association of serum sodium and chloride levels with blood pressure and estimated glomerular filtration rate.Blood Press.2016251515710.3109/08037051.2015.109071126434759
     [Google Scholar]
  75. GuderW.G. HofmannW. Markers for the diagnosis and monitoring of renal tubular lesions.Clin. Nephrol.1992381S3S71295706
     [Google Scholar]
  76. Herrero-MorínJ. MálagaS. FernándezN. ReyC. DiéguezM. SolísG. ConchaA. MedinaA. Cystatin C and beta2-microglobulin: markers of glomerular filtration in critically ill children.Crit. Care2007113R5910.1186/cc592317519026
     [Google Scholar]
  77. BakrA. Al-TonbaryY. OsmanG. El-AshryR. Renal complications of beta-thalassemia major in children.Am. J. Blood Res.2014411625232499
     [Google Scholar]
  78. BhandariS. GalanelloR. Renal aspects of thalassaemia a changing paradigm.Eur. J. Haematol.201289318719710.1111/j.1600‑0609.2012.01819.x22687050
     [Google Scholar]
  79. KorenG. BenturY. StrongD. HarveyE. KleinJ. BaumalR. SpielbergS.P. FreedmanM.H. Acute changes in renal function associated with deferoxamine therapy.Am. J. Dis. Child.19891439107710802486554
     [Google Scholar]
  80. GalanelloR. Deferiprone in the treatment of transfusion-dependent thalassemia: A review and perspective.Ther. Clin. Risk Manag.20073579580518473004
     [Google Scholar]
  81. RheaultM.N. BechtelH. NegliaJ.P. KashtanC.E. Reversible Fanconi syndrome in a pediatric patient on deferasirox.Pediatr. Blood Cancer201156467467610.1002/pbc.2271121298760
     [Google Scholar]
  82. HuangX.P. ThiessenJ.J. SpinoM. TempletonD.M. Transport of iron chelators and chelates across MDCK cell monolayers: Implications for iron excretion during chelation therapy.Int. J. Hematol.201091340141210.1007/s12185‑010‑0510‑320213118
     [Google Scholar]
  83. ZamboniG. MarradiP. TagliaroF. DorizziR. TatòL. Parathyroid hormone, calcitonin and vitamin D metabolites in beta-thalassaemia major.Eur. J. Pediatr.19861451-213313610.1007/BF004418753015625
     [Google Scholar]
  84. SumboonnanondaA. MalasitP. TanphaichitrV.S. Ong-ajyoothS. PetraratS. VongjiradA. Renal tubular dysfunction in α-thalassemia.Pediatr. Nephrol.200318325726010.1007/s00467‑003‑1067‑712644919
     [Google Scholar]
/content/journals/cmc/10.2174/0109298673250805230922054406
Loading
Biochemical Markers of Early Renal Dysfunction in Patients with β-thalassemia Major: A Systematic Review and Meta-analysis
Curr. Med. Chem. 32, 2572 (2025); https://doi.org/10.2174/0109298673250805230922054406
/content/journals/cmc/10.2174/0109298673250805230922054406
/content/journals/cmc/10.2174/0109298673250805230922054406
Loading

Data & Media loading...

Supplements

Supplementary material and PRISMA checklist are available on the publisher’s website along with the published article.

file format download Download

  • Article Type:     Review Article
Keyword(s): renal insufficiency; serum cystatin C; urinary albumin/creatinine ratio; urinary beta 2-microglobulin; urinary N-acetyl-beta-D-glucosaminidase; β-thalassemia major

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test